Here, a genetically inactivated RUNX2, which lacked the transactivation domain, eliminated the original potential of the tumor cells to regulate osteogenic differentiation in bone marrow stromal cells in vitro and their ability to induce osteolytic disease in vivo [125]. The gene discussed is RUNX2; the disease is neoplasm.